Copaiba Balsam




Copaiba Balsam 
Copaifera officinalis, 100% essential oil


Botanical name: Copaifera officinalis
Origin: Brazil
Plant part: Resin, steam distilled
Chemical family:
Sesquiterpenes 83.2%, Sesquiterpenols 3.4%, Monoterpenes 2.8%
Main components: β-caryophyllene 42.87
%, germacrene D 8.62%, α-humulene 6.4%
Shelf life: suggested 8 years

Aroma: Base note.  Balsamic, earthy, resinous, warm, sweet

Therapeutic properties:

**Analgesic: helps to manage pain and inflammation
**Decongestant:  supportive for the lungs and congestion
**Expectorant:  has expectorant qualities to promote healthy respiratory
**Anti-bacterial: helps to reduce unwanted bacteria
**Anti-fungal: effective anti-fungal activity
**Anti-microbial: reduces unwanted bacteria
**Immunostimulant: anti-inflammatory and anti-microbial actions can help strengthen the immune system
**Emotional: very healing and supporting, helps to calm the  mind.  Restless minds can benefit from this oil which promotes focus.  

Suggestions: Add to cream, massage blends, diffuser, sprays, balms, aromatherapy inhalers.  Add to your mix of respiratory oils for supportive lung health during cold and flu. 

Safety: No known safety issues with this oil.

Available in 5ml and 15ml euro dropper bottles. 100% essential oil.

*****This information has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease. As with all essential oils, never use them undiluted, in eyes or mucous membranes. Do not overuse. Do not take internally unless working with a qualified and expert practitioner. Keep away from children. If applying an essential oil to your skin always perform a small patch test to an insensitive part of the body. Consult your doctor or qualified aromatherapist for the safety of using essential oils if pregnant, planning to become pregnant, nursing or if on medications.

Product Options
Combination of product variants is not available
Product in stock

Price: from $3.85

Loading Updating cart...

Comments are closed.